Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Income from Continuing Operations (2016 - 2025)

Adma Biologics' Income from Continuing Operations history spans 13 years, with the latest figure at 49379000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 55.87% year-over-year to 49379000.0; the TTM value through Dec 2025 reached 146930000.0, down 25.67%, while the annual FY2025 figure was 146930000.0, 25.67% down from the prior year.
  • Income from Continuing Operations reached 49379000.0 in Q4 2025 per ADMA's latest filing, up from 36428000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 111896000.0 in Q4 2024 to a low of 18821986.0 in Q2 2021.
  • Average Income from Continuing Operations over 5 years is 10730350.0, with a median of 1903000.0 recorded in 2023.
  • Peak YoY movement for Income from Continuing Operations: soared 1299.96% in 2024, then crashed 55.87% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 16504574.0 in 2021, then rose by 28.55% to 11792616.0 in 2022, then soared by 189.84% to 10594000.0 in 2023, then surged by 956.22% to 111896000.0 in 2024, then plummeted by 55.87% to 49379000.0 in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Income from Continuing Operations are 49379000.0 (Q4 2025), 36428000.0 (Q3 2025), and 34219000.0 (Q2 2025).